Skip to main content

PRESS RELEASES

Date Title  
Toggle Summary Seres Therapeutics to Present at Two Upcoming May Conferences
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 4, 2018-- Seres Therapeutics, Inc . (NASDAQ:MCRB) today announced it will attend each of the following upcoming healthcare conferences: Deutsche Bank 43 rd Annual Health Care Conference : The company will participate in 1x1 meetings on Wednesday, May 9 in
Toggle Summary Seres Therapeutics Presents New Preclinical Data Supporting the Development of Microbiome Therapeutics for Immuno-Oncology at the 2018 American Association for Cancer Research Annual Meeting
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 17, 2018-- Seres Therapeutics, Inc . (NASDAQ:MCRB) today announced that new preclinical data supporting the development of microbiome therapeutics for immuno-oncology (leveraging gut microbiota to impact tumor immunotherapy) 1 will be presented today by
Toggle Summary Seres Therapeutics to Present at Two Upcoming March Conferences
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 9, 2018-- Seres Therapeutics, Inc . (NASDAQ:MCRB) today announced it will present at each of the following upcoming healthcare conferences: The 38 th Annual Cowen & Co. Health Care Conference : a corporate overview will be presented on Wednesday, March 14 at
Toggle Summary Seres Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Updates
- Positive SER-287 Phase 1b clinical and microbiome results support further development; Company plans to initiate next clinical trial in mid-2018 - - Preliminary Phase 1b study data obtained for SER-262, the first ever rationally-designed fermented microbiome therapeutic candidate evaluated in
Toggle Summary Seres Therapeutics to Host Fourth Quarter 2017 Financial Results and Operational Progress Conference Call and Webcast on March 8, 2018
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 2, 2018-- Seres Therapeutics, Inc . (NASDAQ:MCRB) today announced that management will host a conference call and live audio webcast on March 8, 2018 at 8:00 a.m. ET to discuss fourth quarter 2017 results and provide a general business update.
Toggle Summary Seres Therapeutics Announces Appointment of Eric D. Shaff to Additional Role of Chief Operating Officer
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 31, 2018-- Seres Therapeutics, Inc. , (NASDAQ:MCRB) today announced the appointment of Eric D. Shaff to the additional role of Chief Operating Officer. Mr. Shaff has been Executive Vice President and Chief Financial Officer since joining the Company in
Toggle Summary Seres Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 4, 2018-- Seres Therapeutics, Inc . (NASDAQ:MCRB) today announced that it will present at the 36 th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Thursday, January 11 at 8:30 a.m. PT . A live audio webcast of the presentation and breakout
Toggle Summary Seres Therapeutics Reports SER-287 Phase 1b Microbiome Analyses that Provide Mechanistic Support for Clinical Efficacy in Ulcerative Colitis
- Microbiome analyses demonstrate engraftment of SER-287-derived bacteria; microbiome compositional changes correlate with clinical remission - - SER-287 engraftment maintained four weeks after completion of dosing - - Company to discuss proposed SER-287 development plan with FDA and intends to
Toggle Summary Seres Therapeutics Announces FDA Orphan Drug Designation for SER-287 in Treatment of Pediatric Ulcerative Colitis
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 4, 2017-- Seres Therapeutics, Inc. , (NASDAQ:MCRB) today announced that the U.S. Food and Drug Administration ( FDA ) has granted Orphan Drug Designation to microbiome therapeutic candidate SER-287 for the treatment of Ulcerative Colitis (UC) in pediatric
Toggle Summary Seres Therapeutics, MD Anderson Cancer Center, and the Parker Institute for Cancer Immunotherapy Announce a Collaboration to Support the Investigation of Microbiome Therapeutics for Immuno-Oncology
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 14, 2017-- Seres Therapeutics, Inc. (NASDAQ:MCRB), The University of Texas MD Anderson Cancer Center (MD Anderson), and the Parker Institute for Cancer Immunotherapy ( Parker Institute ) today announced a collaboration to evaluate the potential of Seres’

Back to top